STC:DBD's Return-on-Tangible-Equity is ranked better than 75.95% of 898
companies
in the Drug Manufacturers industry
Industry Median: 7.88
vs STC:DBD: 17.84
Binh Dinh Pharmaceutical And Medical Equipment JSC (STC:DBD) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Binh Dinh Pharmaceutical And Medical Equipment JSC Return-on-Tangible-Equity Related Terms
Binh Dinh Pharmaceutical And Medical Equipment JSC Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Binh Dinh Pharmaceutical And Medical Equipment JSC Return-on-Tangible-Equity Chart
Binh Dinh Pharmaceutical And Medical Equipment JSC Annual Data
STC:DBD vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Binh Dinh Pharmaceutical And Medical Equipment JSC's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Binh Dinh Pharmaceutical And Medical Equipment JSC Return-on-Tangible-Equity vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 19.12% mean?
Binh Dinh Pharmaceutical And Medical Equipment JSC (STC:DBD) has a Return-on-Tangible-Equity of 19.12% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Binh Dinh Pharmaceutical And Medical Equipment JSC and its competitors. This is near median its historical median of 18.67. Over the past decade, Binh Dinh Pharmaceutical And Medical Equipment JSC's Return-on-Tangible-Equity has ranged from 16.58 to 20.51. According to the industry distribution chart, Binh Dinh Pharmaceutical And Medical Equipment JSC ranks #216 out of 898 companies in the Drug Manufacturers industry, placing it in the top 24.1%.
Is Binh Dinh Pharmaceutical And Medical Equipment JSC's Return-on-Tangible-Equity too high?
Binh Dinh Pharmaceutical And Medical Equipment JSC's current Return-on-Tangible-Equity of 19.12% is near median its 10-year median of 18.67. Over the past 10 years, this metric has ranged from a low of 16.58 to a high of 20.51. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.88. Binh Dinh Pharmaceutical And Medical Equipment JSC's value of 19.12% is 142.6% above this industry median. Based on the distribution chart, Binh Dinh Pharmaceutical And Medical Equipment JSC ranks #216 out of 898 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Binh Dinh Pharmaceutical And Medical Equipment JSC has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Binh Dinh Pharmaceutical And Medical Equipment JSC's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Binh Dinh Pharmaceutical And Medical Equipment JSC ranks #216 out of 898 companies for Return-on-Tangible-Equity. This places Binh Dinh Pharmaceutical And Medical Equipment JSC in the top 24% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.88. Binh Dinh Pharmaceutical And Medical Equipment JSC's value of 19.12% is 142.6% above this benchmark. Historically, Binh Dinh Pharmaceutical And Medical Equipment JSC's own Return-on-Tangible-Equity has ranged from 16.58 to 20.51 over the past decade. While the company's 10-year median is 18.67 vs. the industry median of 7.88, Binh Dinh Pharmaceutical And Medical Equipment JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.88, based on 898 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Binh Dinh Pharmaceutical And Medical Equipment JSC's current Return-on-Tangible-Equity of 19.12% is 142.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Binh Dinh Pharmaceutical And Medical Equipment JSC and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Binh Dinh Pharmaceutical And Medical Equipment JSC's current Return-on-Tangible-Equity is 19.12%, which is near median its own 10-year median of 18.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Binh Dinh Pharmaceutical And Medical Equipment JSC stock overvalued right now?
Based on GuruFocus' analysis, Binh Dinh Pharmaceutical And Medical Equipment JSC (STC:DBD) is currently considered Fairly Valued. The stock's GF Value™ is ₫52,287.92, compared to a current price of ₫52,000.00 — trading 0.6% below its estimated fair value. The current Return-on-Tangible-Equity is 19.12%, which is near median its 10-year median of 18.67 and 142.6% above the Drug Manufacturers industry median of 7.88. Binh Dinh Pharmaceutical And Medical Equipment JSC's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Binh Dinh Pharmaceutical And Medical Equipment JSC (STC:DBD), the current Return-on-Tangible-Equity is 19.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Binh Dinh Pharmaceutical And Medical Equipment JSC (STC:DBD) Overvalued in 2026?
Based on GuruFocus' analysis, Binh Dinh Pharmaceutical And Medical Equipment JSC stock appears to be undervalued.
The current stock price of ₫52,000.00 is trading 0.6% below its estimated GF Value™ of ₫52,287.92.
GuruFocus considers Binh Dinh Pharmaceutical And Medical Equipment JSC to be Fairly Valued.
Key valuation signals for STC:DBD:
Return-on-Tangible-Equity: 19.12% (near median its 10-year median of 18.67)
GF Value™: ₫52,287.92 vs. price of ₫52,000.00 (0.6% below fair value)
Industry Position: 142.6% above the Drug Manufacturers median (#216 of 898)
No single metric tells the full story. See the STC:DBD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Binh Dinh Pharmaceutical And Medical Equipment JSC Business Description
Binh Dinh Pharmaceutical And Medical Equipment JSC is a pharmaceutical company. The company is engaged in production and trade of pharmaceutical products, medicinal herbs, pharmaceutical and medical equipment.
82GF Score
Get the complete analysis for STC:DBD
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DBD has been successfully added to your 
